Tiziana enrolls second patient in ongoing intranasal foralumab evaluation for secondary progressive multiple sclerosis

- clinical data from the first patient, after completing 3 out of 6 months, suggest that the treatment was well tolerated with a favorable clinical response

TLSA Ratings Summary

TLSA Quant Ranking